Online inquiry

IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ265MR)

This product GTTS-WQ265MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets EPCAM gene. The antibody can be applied in Colon Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4072
UniProt ID P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ265MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11762MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ14352MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ8433MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ13692MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ13990MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ14562MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ4330MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ11967MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW